Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2

In patients with acute myeloid leukemia (AML), treatment with histamine dihydrochloride (HDC) and low-dose IL-2 (HDC/IL-2) in the post-chemotherapy phase has been shown to reduce the incidence of leukemic relapse. The clinical benefit of HDC/IL-2 is pronounced in monocytic forms of AML, where the le...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiffin, Roberta, Grauers Wiktorin, Hanna, Nilsson, Malin S., Aurelius, Johan, Aydin, Ebru, Lenox, Brianna, Nilsson, Jonas A., Ståhlberg, Anders, Thorén, Fredrik B., Hellstrand, Kristoffer, Martner, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015904/
https://www.ncbi.nlm.nih.gov/pubmed/29967760
http://dx.doi.org/10.3389/fonc.2018.00218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015904/
https://www.ncbi.nlm.nih.gov/pubmed/29967760
http://dx.doi.org/10.3389/fonc.2018.00218

Ejemplares similares